Quercetin in Coronary Artery By-pass Surgery

NCT04907253 | Completed Phase 2 Results

• 1 other identifier: 2021-2761
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to test the anti-inflammatory and anti-senescence effects of quercetin during coronary artery by-pass graft surgery.

Conditions

Coronary Artery Disease

Keywords

Inflammation; Endothelium; Senescence; Vascular reactivity

Outcome Measures

Primary Outcomes (2)

• Quercetin-associated Change in Surgery-associated Inflammation

  Circulating blood levels of hs-CRP (mg/L) will be measured as well as a panel of circulating inflammatory markers in a subgroup of patients at day 5 post-surgery

  Baseline, 1 day and 4 days post-surgery

• Quercetin-associated Change in Surgery-associated Marker of Senescence

  Circulating blood levels of ANGPTL2 (ng/L) will be measured in addition to additional circulating markers of inflammation in a sub-group of patients at day 4 post-surgery

  Baseline, 1 day and 4 days post-surgery

Secondary Outcomes (1)

• Acetylcholine Concentration (nM) Required for EC50 in Endothelium-dependent Relaxation

  During surgery

Other Outcomes (1)

• Patient Follow-up

  Three month post-surgery

Study Arms (2)

Quercetin

ACTIVE COMPARATOR

Patients receiving 500 mg quercetin twice daily

Drug: Quercetin

Placebo

PLACEBO COMPARATOR

Patients receiving placebo twice daily

Drug: Placebo

Interventions

Quercetin DRUG

500 mg twice daily

Quercetin

Placebo DRUG

twice daily

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• to be able to speak French or English;
• to be able to give free and enlighten consent;
• be hospitalized and waiting for a cardiac surgery of revascularization;
• to have had a myocardial infarction (MI) within the past 30 days or to be in a state of stable angina before the surgery.

You may not qualify if:

• to be in a stable state without MI in the last 30 days;
• have a cardiac surgery concomitant to the cardiac surgery of revascularization;
• have an infection in the last 30 days;
• to have renal insufficiency (GFR less than 30);
• to have a liver disease (AST, ALT or bilirubin ˃ 2X normal values);
• to have a known cirrhosis;
• to have a past history of breast cancer or other tumors estrogen-dependent;
• to be intolerant to flavonoids, niacine or ascorbic acid;
• take quinolone;
• need for a quinolone during post-op;
• not being able to give a free and enlighten consent;
• not being able to speak French of English;
• take quercetin as a supplement.

Sponsors & Collaborators

• Montreal Heart Institute: lead

Study Sites (1)

Montreal Heart Institute

Montreal, Quebec, H1T 1C8, Canada

Location

Related Publications (3)

• Noly PE, Labbe P, Thorin-Trescases N, Fortier A, Nguyen A, Thorin E, Carrier M. Reduction of plasma angiopoietin-like 2 after cardiac surgery is related to tissue inflammation and senescence status of patients. J Thorac Cardiovasc Surg. 2019 Sep;158(3):792-802.e5. doi: 10.1016/j.jtcvs.2018.12.047. Epub 2019 Jan 8.

  PMID: 30745045 BACKGROUND

• Mury P, Dagher O, Fortier A, Diaz A, Lamarche Y, Noly PE, Ibrahim M, Page P, Demers P, Bouchard D, Bernier PL, Poirier N, Moss E, Durrleman N, Jeanmart H, Pellerin M, Lettre G, Thorin-Trescases N, Carrier M, Thorin E. Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients. Aging Cell. 2025 Aug;24(8):e70108. doi: 10.1111/acel.70108. Epub 2025 May 15.

  PMID: 40375481 RESULT

• Dagher O, Mury P, Noly PE, Fortier A, Lettre G, Thorin E, Carrier M. Design of a Randomized Placebo-Controlled Trial to Evaluate the Anti-inflammatory and Senolytic Effects of Quercetin in Patients Undergoing Coronary Artery Bypass Graft Surgery. Front Cardiovasc Med. 2021 Oct 20;8:741542. doi: 10.3389/fcvm.2021.741542. eCollection 2021.

  PMID: 34746258 DERIVED

MeSH Terms

Conditions

Coronary Artery Disease; Inflammation

Interventions

Quercetin

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Flavonols; Flavonoids; Chromones; Benzopyrans; Pyrans; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Results Point of Contact

• Title: Dr Eric Thorin
• Organization: Montreal Heart Institute

eric.thorin@umontreal.ca

514-376-3330

Study Officials

• Michel Carrier, MD

  Montreal Heart Institute

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Allocation of randomization numbers by the pharmacist provided as a randomization list prepared by the biostatisticians of the Montreal Heart Institute
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Randomized, double-blind, placebo-controlled

Study Record Dates

• First Submitted: May 12, 2021
• First Posted: May 28, 2021
• Study Start: June 4, 2021
• Primary Completion: December 1, 2023
• Study Completion: May 16, 2025
• Last Updated: April 15, 2026
• Results First Posted: April 15, 2026

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)